Case Studies

2024-11-05

Protein Expression & Case Studies | AtaGenix Recombinant Protein Solutions

This study demonstrates the optimization of E. coli expression systems for recombinant protein and antibody fragment production. Strategies included host strain selection, periplasmic expression for proper folding, and refolding inclusion bodies into active soluble proteins. Results showcase high-quality protein expression and QC validation.

2024-11-05

Antibody Gene Sequencing and Validation Case Study | AtaGenix Custom Antibody Development

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.

2024-11-04

Recombinant Antibody Expression | AtaGenix Custom Antibody Services

This case study demonstrates the use of the insect-baculovirus expression system for efficient production of recombinant proteins. The approach achieved high yields with proper folding and post-translational modifications, showcasing its reliability for complex protein expression.

2024-11-04

Xten™ Mab Single B Rabbit Monoclonal Antibody Development Case Study

Using rabbit single B-cell antibody technology, an Anti-human CD86 rabbit monoclonal antibody was developed. Rabbits with serum titers greater than 128K were selected, and PBMCs were isolated for flow sorting to obtain human CD86 antigen-specific B-cell plates.

2024-11-04

SARS-CoV-2 Spike Protein Expression & Purification | AtaGenix High-Yield Mammalian System

The results show that the SARS-CoV-2 S protein expressed in mammalian cells achieved high yields during purification, with clear target protein bands observed in elution fractions (E1-E8) and minimal impurities.

2024-10-21

XtenCHO™ High-Density Expression System

AtaGenix's XtenCHO™ high-density expression system demonstrates exceptional proliferation and yield advantages in therapeutic antibody production. Cells cultured in this system maintain high density and viability over 15 days, ensuring healthy growth. The system shows strong adaptability and production efficiency across various antibodies, providing robust support for efficient and stable therapeutic antibody manufacturing.